[ad_1]
Our current article on Illumina (ILMN), through which we requested if it was time to dump the genomics firm, elicited pushback from readers. To very briefly sum up a lot of the feedback: A few of you argued that we’re simply on the daybreak of the genetics-sequencing revolution in healthcare, and Illumina is the corporate greatest positioned to learn. We completely agree with the primary half of that assertion. Nonetheless, Illumina shouldn’t be the identical firm it was just some years in the past. We’ve documented the corporate’s varied fumbles, culminating within the unsanctioned acquisition of former spin-off Grail in August 2021. Maybe with a brand new management crew on the helm they’ll be capable to return to progress, however we don’t put money into turnaround tales.
In protection of Ilumina, one other reader identified that the “largest gamers within the area such Danaher, Thermo Fisher, Roche, and Agilent are all down 25-35% off their highs and aren’t taking a look at stellar 2024s both.” Truthful sufficient, we’ve been listening to about “macroeconomic” headwinds for greater than a 12 months now, however there are many causes to imagine that the chief in genomics ought to be rising, not faltering.
Molecular Most cancers Diagnostics Market Rising Quick
We’ve already mentioned how Illumina could also be slipping on the know-how entrance or dealing with stiffer competitors from China. Maybe there’s additionally merely a worldwide glut of gene-sequencing machines; in spite of everything, million-dollar sequencers aren’t smartphones that you just improve each two years. One brilliant spot from the corporate’s Q3-2023 report: 10% year-over-year income progress in medical sequencing consumables, led by oncology and genetic-disease testi
[ad_2]
Source link
